Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | POLB | P06746 | 1/20 | 0.42 |
| ▸ | CHRNB4 | P30926 | 7/20 | 0.38 |
| ▸ | CHRNA3 | P32297 | 7/20 | 0.38 |
| ▸ | CHRNB2 | P17787 | 8/20 | 0.37 |
| ▸ | CHRNA4 | P43681 | 8/20 | 0.37 |
| ▸ | PKM | P14618 | 1/20 | 0.36 |
| ▸ | LMNA | P02545 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30827640 | 0.80 | POLB (0.41) | POLBCHRNB4CHRNA3CHRNB2CHRNA4 | |
| SCHEMBL28158371 | 0.76 | CYP11B2 (0.42) | CHRNB4CHRNA3CHRNB2CHRNA4 | |
| SCHEMBL30292820 | 0.76 | SIGMAR1 (0.38) | LMNA | |
| SCHEMBL21815682 | 0.76 | SIGMAR1 (0.38) | LMNA | |
| SCHEMBL29363156 | 0.74 | SIGMAR1 (0.36) | LMNA | |
| SCHEMBL22028459 | 0.74 | SIGMAR1 (0.36) | LMNA | |
| SCHEMBL28423984 | 0.74 | SIGMAR1 (0.36) | LMNA | |
| SCHEMBL30919258 | 0.74 | SIGMAR1 (0.36) | LMNA | |
| SCHEMBL1408252 | 0.74 | SIGMAR1 (0.36) | LMNA | |
| SCHEMBL30679849 | 0.74 | SIGMAR1 (0.36) | LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4590397-A1 | PCSK9 INHIBITORS AND METHODS OF USE THEREOF | Astrazeneca AB (SE) | 2025-07-30 | — | — | EP | disclosed |
| EP-4590396-A1 | PCSK9 INHIBITORS AND METHODS OF USE THEREOF | Astrazeneca AB (SE) | 2025-07-30 | — | — | EP | disclosed |
| US-20240228469-A1 | PCSK9 INHIBITORS AND METHODS OF USE THEREOF | ASTRAZENECA AB (SE) | 2024-07-11 | — | — | US | disclosed |
| US-20240217951-A1 | PCSK9 INHIBITORS AND METHODS OF USE THEREOF | ASTRAZENECA AB (SE) | 2024-07-04 | — | — | US | disclosed |
| WO-2024062089-A1 | PCSK9 INHIBITORS AND METHODS OF USE THEREOF | ASTRAZENECA AB (SE) | 2024-03-28 | — | — | WO | disclosed |
| WO-2024062090-A1 | PCSK9 INHIBITORS AND METHODS OF USE THEREOF | ASTRAZENECA AB (SE) | 2024-03-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240228469-A1 | PCSK9 INHIBITORS AND METHODS OF USE THEREOF | PCSK9, PCSK7, PCSK6 | POLB 2696/4885CHRNB4 2673/4885CHRNA3 3231/4885 |
| US-20240217951-A1 | PCSK9 INHIBITORS AND METHODS OF USE THEREOF | PCSK9, PCSK7, PCSK6 | POLB 3429/4885CHRNB4 3487/4885CHRNA3 3544/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.